Compass Therapeutics (CMPX) Assets Average (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Assets Average for 3 consecutive years, with $225.4 million as the latest value for Q4 2025.
- Quarterly Assets Average rose 55.7% to $225.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $225.4 million through Dec 2025, up 55.7% year-over-year, with the annual reading at $180.0 million for FY2025, 21.1% up from the prior year.
- Assets Average hit $225.4 million in Q4 2025 for Compass Therapeutics, up from $174.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $225.4 million in Q4 2025 to a low of $124.1 million in Q2 2025.
- Historically, Assets Average has averaged $163.2 million across 3 years, with a median of $159.0 million in 2024.
- Biggest YoY gain for Assets Average was 55.7% in 2025; the steepest drop was 21.66% in 2025.
- Year by year, Assets Average stood at $163.5 million in 2023, then dropped by 11.43% to $144.8 million in 2024, then soared by 55.7% to $225.4 million in 2025.
- Business Quant data shows Assets Average for CMPX at $225.4 million in Q4 2025, $174.0 million in Q3 2025, and $124.1 million in Q2 2025.